Navigation Links
OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
Date:1/10/2011

REDWOOD CITY, Calif., Jan. 10, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced that patient dosing has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers.  

OMP-59R5 is a monoclonal antibody that binds selected Notch receptors and is the first antibody to specifically block these targets to enter human studies.  The Phase 1 clinical trial of OMP-59R5 is a single-agent study designed to evaluate the safety of escalating doses of OMP-59R5 in patients who have received prior treatment with standard chemotherapeutics.  The study will also assess pharmacokinetics, biomarkers and initial indications of efficacy.  The Phase 1 trial is being conducted at leading U.S. cancer treatment centers.  Preclinical studies have demonstrated that OMP-59R5 decreases the frequency of tumor-initiating cells across a variety of tumor types.  

"The advancement of our second antibody into the clinic represents an important milestone for OncoMed, demonstrating our robust and productive drug discovery capabilities and steady execution on our objectives for our programs," said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.  "In just a few short years, we have established a rich pipeline of first-in-class anti-cancer stem cell therapeutics with the potential to dramatically transform cancer treatment by directly targeting tumor-initiating cells."  

OMP-59R5 is part of OncoMed's collaboration with GlaxoSmithKline (GSK) and its advancement to the clinic triggers a milestone payment from GSK for the company.  In December 2007, OncoMed and GSK entered into a strategic alliance valued at up to $1.4 billion to develop cancer stem cell antibody therapeutics targeting the Notch signaling pathway.  OncoMed is currently conducting Phase 1 single agent and Phase 1b combination studies of its first Notch-pathway candidate, OMP-21M18, in patients with a variety of advanced solid tumors.  Preliminary results from OncoMed's Phase 1 dose-escalating single-agent study of OMP-21M18 demonstrate positive indications of disease control and tumor responses as measured by RECIST criteria.  In addition, biomarker measurements show that OMP-21M18 is a potent inhibitor of Notch signaling.  Initial data from this ongoing study were presented at the 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" held November 16-19, 2010 in Berlin, Germany.

About Cancer Stem Cells

Cancer stem cells, a small, resilient subset of cells found in tumors, have the capacity to self-renew and differentiate, leading to tumor initiation and driving tumor growth, recurrence and metastasis.  Also referred to as "tumor-initiating cells," these cells were first discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumor cancers, including cancer of head and neck, lung, prostate, pancreas and glioblastoma.  Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy.  OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways which are thought to be critical to the activity and survival of cancer stem cells.  OncoMed's antibody therapeutics target cancer stem cell proteins and have the potential to be developed against a range of tumor types.  

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis.  A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers.  OncoMed has advanced two anti-cancer stem cell monoclonal antibodies into the clinic, OMP-21M18 and OMP-59R5, which both target the Notch signaling pathway.  In addition, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways.  OncoMed has formed strategic alliances with Bayer Schering Pharma and GlaxoSmithKline.  Privately-held, OncoMed's investors include:  US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.  Additional information can be found at the company's website: www.oncomed.com.


'/>"/>
SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
4. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)...  As a teenager, an active and athletic ... his heart. He continued enjoying sports and recreation throughout ... heart was giving out and he was a few ... the Mesa, Arizona resident received ... heart transplant, the SynCardia TAH-t is the only approved ...
(Date:5/3/2016)... ORANGE COUNTY, Calif. , May 3, 2016  While you may be familiar with watching ... 4K resolution , also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is ... class manufacturer of innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new article ... Bible about helping to stop cancer. Yisrayl says there are too many suffering and dying ... and science industries will pay close attention and take action. The Pastor says that the ...
(Date:5/6/2016)... ... 06, 2016 , ... This Mother’s Day kicks off the start of an ... National Women’s Health Week takes place May 8-May 14. , Throughout the celebration, ... empower women to make their health a top priority. Women everywhere are being encouraged ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, ... Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and ... Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... select performance in the industry’s gold standard KLAS Performance Report, Epic ... Consulting report assessed organizations that specialize in consulting services for electronic health record ...
(Date:5/5/2016)... Illinois (PRWEB) , ... May 05, 2016 , ... ... its “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit their ... a “tobacco product,” apply to all vaping products that entered the market since ...
Breaking Medicine News(10 mins):